Coya Therapeutics, Inc. (COYA)

In October 2025, Coya Therapeutics announced the pricing and closing of an upsized public offering of common stock. In November 2025, the company reported its Third Quarter Financial Results, provided a corporate update, announced positive preclinical in-vivo animal study results for COYA 303, and participated in investor relations and clinical trials conferences. In December 2025, Coya Therapeutics announced that patients have been dosed in the ALSTARS Trial of COYA 302 for the treatment of ALS, and Health Canada accepted the Clinical Trial Application for COYA 302 for ALS. In January 2026, the U.S. Food and Drug Administration accepted Coya's Investigational New Drug application for COYA 302 for the treatment of Frontotemporal Dementia. The company's share price experienced a decline of 18.76% between January 13, 2025, and January 9, 2026. More recently, the stock had fallen by 24.64% in the past month and 17.57% in the previous week.

There is no indication of demand seasonality for Coya Therapeutics' products or services. The demand for such therapies, once approved, would be driven by the prevalence and incidence of these chronic conditions and the medical need for effective treatments, rather than seasonal fluctuations.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that modulate regulatory T cells to address systemic inflammation and neuroinflammation associated with neurodegenerative, autoimmune, and metabolic diseases. The company's investigational product pipeline utilizes multiple therapeutic modalities, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. COYA 302 is the lead investigational candidate, a combination of COYA 301 and CTLA4-Ig, being developed for ALS, FTD, Parkinson's disease, and Alzheimer's disease. COYA 301 is Coya's proprietary low-dose interleukin-2, intended to enhance the anti-inflammatory function of Tregs. COYA 303 is an investigational biologic combination of low-dose IL-2 and GLP-1 receptor agonists, being explored for inflammatory diseases and has potential in neurodegenerative conditions like Alzheimer's Disease.

Coya Therapeutics, Inc. is headquartered in Houston, Texas, United States. Clinical trials for COYA 302 are being conducted in the United States and Canada. Coya has a development and license agreement with Dr. Reddy's Laboratories for commercialization of COYA 302 in the United States, Canada, the European Union, and the United Kingdom for ALS. Coya retains commercialization rights for COYA 302 in Japan, Mexico, and South American countries.

Coya Therapeutics' brand reputation in the past year appears to be positively influenced by its progress in clinical development and regulatory milestones. The FDA's acceptance of the IND application for COYA 302 for FTD and Health Canada's acceptance of the CTA for COYA 302 for ALS demonstrate regulatory confidence in their investigational therapies. The commencement of dosing in the ALSTARS Trial for ALS and positive interim data from an investigator-initiated study of COYA 302 for FTD highlight the advancement of their pipeline. The ongoing collaboration with Dr. Reddy's Laboratories for COYA 302 and strategic investments underscore external validation and financial support for their research. The CEO's letter to stockholders and participation in investor conferences contribute to transparency and investor relations. Publication of a study linking inflammation and oxidative stress to Parkinson's disease progression further solidifies their scientific credibility. No explicitly negative events significantly impacting Coya Therapeutics' reputation were found in the past year.

Coya Therapeutics, Inc. stock is owned by a mix of institutional, insider, and retail investors. Approximately 22.73% to 39.75% of the stock is held by institutional shareholders, 4.95% to 10.32% by insiders, and a significant portion, around 66.95% to 71.33%, by retail investors. Major institutional owners include DME Capital Management, LP, AIGH Capital Management LLC, Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, CM Management, LLC, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, Dauntless Investment Group, LLC, FSMAX - Fidelity Extended Market Index Fund, and BlackRock, Inc. The largest individual shareholder is Howard Berman, who owns 949,338 shares, representing 4.54% of the company.